This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

LORENZ DrugTrack Solution: Take A Closer Look

FRANKFURT AM MAIN, Germany, March 18, 2013 /PRNewswire/ -- LORENZ Life Sciences Group posed the question "Do you know the value of your xEVMPD data?" at the EuroMeeting held in Amsterdam, Netherlands on March 4 – 6, 2013. 

Introduction The introduction of the xEVMPD standard has major implications for applicants and holders of European Union marketing authorizations, who are required to electronically register each of their approved and pending medicinal products with the EMA in detail. The registration includes all active ingredients and excipients as well as their manufacturers, any varying local substance names, the packaging sizes, quantities, MedDRA codes, ATC codes, administration routes, and the current SPC in the local language.

In response to this new standard, LORENZ has developed drugTrack™ EVMPD, an e-submissions solution specifically tailored to the new EMA requirements. It is available as a stand-alone package to manage xEVMPD submissions, but crucially it is also conceived to work seamlessly with LORENZ drugTrack regulatory lifecycle software.

Track & control your data At the core of drugTrack EVMPD is a wizard for entering the data and for creating correctly formatted xEVPRM messages. Existing submission data can be easily imported from typical information sources, such as Excel spreadsheets, and then managed in the new system.

The built-in messaging management function includes a "second pair of eyes" rule requiring a second person in the organization to approve any system-generated message before it is sent to EMA, and the software also tracks all replies. It will also send email alerts to the user with reminders 120 days in advance of pending deadlines. By capturing every single step in the submission process, drugTrack EVMPD can generate a perfect audit trail report on every submission and every change.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs